← Back to Company DatabaseVisit Website
Modulari-T Biosciences
Synthetic immune receptors for next-generation CAR-T cancer therapy.
Pre-seed / SeedMontreal, CanadaFounded 2021
About
Modulari-T has designed a new family of synthetic genes called MARC (Modular Actuation Receptor Complex) that reprogram immune cells to efficiently recognize and kill cancer cells. Compared to traditional CAR-T, MARC receptors have twice the tumor-clearing power while avoiding immune exhaustion. The Montreal-based company aims to make cell therapy more effective across oncology and beyond.
Total Funding
$500KKey Product
MARC synthetic immune receptor platformGeography
North AmericaKey Investors
Y CombinatorPioneer FundCreative Destruction Lab
Focus Areas
Treatment (Therapeutics)
Technology
Cell TherapyImmunotherapy
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026